---
schema_version: "secwatch.filing_event.v1"
accession: "0001599298-26-000071"
form_type: "8-K"
ticker: "SMMT"
cik: "0001599298"
company_name: "Summit Therapeutics Inc."
filed_at: "2026-08-05T11:32:20+00:00"
generated_at: "2026-08-05T11:35:08.972644+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Summit expands ivonescimab into bladder cancer with Phase II/III HARMONi-GU1 trial

## Summary
- Ivonescimab plus enfortumab vedotin (EV) vs pembrolizumab plus EV as 1L therapy for locally advanced/metastatic urothelial carcinoma.
- Phase II/III trial aims to enroll ~800 patients; Phase III endpoints are PFS and OS.
- Global site activations planned to begin by Q4 2026.
- Ivonescimab now in 16 Phase III trials across multiple tumor types including lung, colorectal, and bladder.

## SEC filing metadata
- accession: 0001599298-26-000071
- form_type: 8-K
- ticker: SMMT
- cik: 0001599298
- company_name: Summit Therapeutics Inc.
- filed_at: 2026-08-05T11:32:20+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000071/0001599298-26-000071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1599298/000159929826000071/smmt-20260805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001599298-26-000071
- JSON: https://secwatch.observer/filing/0001599298-26-000071.json
- Plain text: https://secwatch.observer/filing/0001599298-26-000071.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.